{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:31Z","timestamp":1791318331387,"version":"4.3.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.neuropharm.2020.108442","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:55:38Z","timestamp":1610499338000},"page":"108442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research"],"prefix":"10.1016","volume":"185","author":[{"given":"Valentina","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108442_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopha.2017.12.056","article-title":"Orphan G protein-coupled receptors: the role in CNS disorders","volume":"98","author":"Alavi","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108442_bib2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/FBP.0000000000000565","article-title":"Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice","volume":"31","author":"Assareh","year":"2020","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fnbeh.2020.00032","article-title":"Cannabidiol (CBD) inhibited rhodamine-123 efflux in cultured vascular endothelial cells and astrocytes under hypoxic conditions","volume":"14","author":"Auzmendi","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108442_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108442_bib6","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","author":"Bansal","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","article-title":"A Phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy","volume":"34","author":"Ben-Menachem","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bcp.14158","article-title":"Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency","volume":"86","author":"Bergmann","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108442_bib98","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108442_bib11","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/molecules23102478","article-title":"Cannabinoid delivery systems for pain and inflammation treatment","volume":"23","author":"Bruni","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2020.108442_bib12","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108442_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cophys.2017.12.007","article-title":"Dravet syndrome: a sodium channel interneuronopathy","volume":"2","author":"Catterall","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/cns.12770","article-title":"Inhibition of transient potential receptor vanilloid type 1 suppresses seizure susceptibility in the genetically epilepsy-prone rat","volume":"24","author":"Cho","year":"2018","journal-title":"CNS Neurosci. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108442_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/ijms21030723","article-title":"Phytocannabinoids in neurological diseases: could they restore a physiological GABAergic transmission?","volume":"21","author":"Cifelli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/epi.16419","article-title":"A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects","volume":"61","author":"Crockett","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108442_bib18","doi-asserted-by":"crossref","first-page":"107861","DOI":"10.1016\/j.neuropharm.2019.107861","article-title":"A perspective on cannabinoids for treating epilepsy: do they really change the landscape?","volume":"170","author":"Cross","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108442_bib19","first-page":"175","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacologia"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108442_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.neuropharm.2020.108442_bib22","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.neuropharm.2020.108442_bib23","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neuropharm.2020.108442_bib24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108442_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials","author":"Devinsky","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2020.108442_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol Elevates mechanistic target of Rapamycin inhibitor levels in patients with tuberous sclerosis complex","volume":"105","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2019.12.006","article-title":"Cannabis-based products for pediatric epilepsy: an updated systematic review","volume":"75","author":"Elliott","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2020.108442_bib28","series-title":"Prescribing Information","author":"Epidiolex","year":"2020"},{"key":"10.1016\/j.neuropharm.2020.108442_bib29","series-title":"Summary of Product Characteristics","author":"Epidyolex","year":"2019"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/glia.23006","article-title":"Microglia-neuron communication in epilepsy","volume":"65","author":"Eyo","year":"2017","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2020.108442_bib31","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.7717\/peerj.153","article-title":"Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines","volume":"1","author":"Feinshtein","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.neuropharm.2020.108442_bib32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108442_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-020-00931-w","article-title":"The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations","author":"Franco","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"issue":"43","key":"10.1016\/j.neuropharm.2020.108442_bib35","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108442_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.expneurol.2013.10.010","article-title":"TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo","volume":"250","author":"Gonzalez-Reyes","year":"2013","journal-title":"Exp. Neurol."},{"issue":"S1","key":"10.1016\/j.neuropharm.2020.108442_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are Transient Receptor Potential Vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcp.14028","article-title":"Parasitic pharmacology: a plausible mechanism of action for cannabidiol","volume":"86","author":"Groeneveld","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108442_bib40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjp.0707467","article-title":"The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids","volume":"152","author":"Holland","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbi.2015.01.017","article-title":"TRPV1 promotes repetitive febrile seizures by pro-inflammatory cytokines in immature brain","volume":"48","author":"Huang","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108442_bib42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108442_bib43","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/cells9040956","article-title":"Adenosine-related mechanisms in non-adenosine receptor drugs","volume":"9","author":"Jacobson","year":"2020","journal-title":"Cells"},{"issue":"42","key":"10.1016\/j.neuropharm.2020.108442_bib44","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108442_bib45","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening Program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108442_bib46","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/epi.16071","article-title":"Effects of cannabidiol on brivaracetam plasma levels","volume":"60","author":"Klotz","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108442_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fncel.2019.00442","article-title":"Activation of TRPV1 contributes to recurrent febrile seizures via inhibiting the microglial M2 phenotype in the immature brain","volume":"13","author":"Kong","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"17","key":"10.1016\/j.neuropharm.2020.108442_bib48","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108442_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neubiorev.2020.01.014","article-title":"The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: from behavior and mechanisms to clinical insights","volume":"111","author":"Lazarini-Lopes","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108442_bib51","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.neuropharm.2020.108442_bib52","doi-asserted-by":"crossref","first-page":"112163","DOI":"10.1016\/j.ejmech.2020.112163","article-title":"Overview of cannabidiol (CBD) and its analogues: structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease","volume":"192","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108442_bib53","doi-asserted-by":"crossref","first-page":"108156","DOI":"10.1016\/j.neuropharm.2020.108156","article-title":"Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway","volume":"176","author":"Lima","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108442_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib56","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108442_bib57","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00381-020-04726-z","article-title":"Genetics of tuberous sclerosis complex: an update","volume":"36","author":"Marom","year":"2020","journal-title":"Child. Nerv. Syst."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108442_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-017-0599-0","article-title":"Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction?","volume":"57","author":"Martin","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"3945","key":"10.1016\/j.neuropharm.2020.108442_bib59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.169.3945.611","article-title":"The chemical basis of hashish activity","volume":"169","author":"Mechoulam","year":"1970","journal-title":"Science"},{"issue":"37","key":"10.1016\/j.neuropharm.2020.108442_bib60","doi-asserted-by":"crossref","first-page":"13025","DOI":"10.1523\/JNEUROSCI.2589-11.2011","article-title":"The expression pattern of TRPV1 in brain","volume":"31","author":"Menigoz","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108442_bib61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neures.2014.04.006","article-title":"Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats","volume":"84","author":"Mijangos-Moreno","year":"2014","journal-title":"Neurosci. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108442_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/NDT.S203782","article-title":"Cannabinoids in the treatment of epilepsy: current status and future prospects","volume":"16","author":"Morano","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib64","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A Phase 1, open-label, pharmacokinetic ttrial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"S1","key":"10.1016\/j.neuropharm.2020.108442_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/epd.2019.1124","article-title":"The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials","volume":"22","author":"Nabbout","year":"2020","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.neuropharm.2020.108442_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1570159X13666150216222543","article-title":"TRPV1 channel: a potential drug target for treating epilepsy","volume":"13","author":"Naziroglu","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib67","series-title":"The Proposed Multimodal Mechanism of Action of Cannabidiol in Epilepsy: Modulation of Intracellular Calcium and Adenosine-Mediated Signaling. [abstract]","author":"Nichol","year":"2018"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed. Environ. Mass Spectrom."},{"key":"10.1016\/j.neuropharm.2020.108442_bib69","series-title":"Transdermal Cannabidiol (CBD) Gel for the Treatment of Focal Epilepsy in Adults. [abstract]","author":"O'Brien","year":"2018"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J. Epilepsy Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108442_bib72","series-title":"Cannabidiol Drug-Drug Interaction with Other Commonly Used Antiepileptic Drugs Clobazam or Valproate in an Acute Mouse Model of Generalized Seizures [abstract]","author":"Rana","year":"2019"},{"issue":"23","key":"10.1016\/j.neuropharm.2020.108442_bib73","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.1074\/jbc.M707104200","article-title":"Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol","volume":"283","author":"Ross","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108442_bib74","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/epi.14574","article-title":"A novel GABAergic dysfunction in human Dravet syndrome","volume":"59","author":"Ruffolo","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108442_bib75","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","article-title":"Cannabidiol: a review of clinical efficacy and safety in epilepsy","volume":"96","author":"Samanta","year":"2019","journal-title":"Pediatr. Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108442_bib76","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.3390\/ijms21114096","article-title":"Reactive glia inflammatory signaling pathways and epilepsy","volume":"21","author":"Sanz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib77","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.3390\/ph13080174","article-title":"Receptors and channels possibly mediating the effects of phytocannabinoids on seizures and epilepsy","volume":"13","author":"Senn","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2020.108442_bib78","doi-asserted-by":"crossref","first-page":"1235\u20101241","DOI":"10.1007\/s10072-014-1689-5","article-title":"Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala kindling in male rats","volume":"35","author":"Shirazi","year":"2014","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib79","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/2193-1801-2-236","article-title":"A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers","volume":"2","author":"Stott","year":"2013","journal-title":"SpringerPlus"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/s12249-018-1239-1","article-title":"Critical in vitro characterization methods of lipid-based formulations for oral delivery: a comprehensive review","volume":"20","author":"Swarnakar","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"13","key":"10.1016\/j.neuropharm.2020.108442_bib81","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108442_bib82","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108442_bib83","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108442_bib84","series-title":"Cannabidiol (CBD) Treatment in Patients with Seizures Associated with Tuberous Sclerosis Complex: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (GWPCARE6). [abstract]","author":"Thiele","year":"2019"},{"key":"10.1016\/j.neuropharm.2020.108442_bib85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ebcr.2017.10.001","article-title":"An interaction between warfarin and cannabidiol, a case report","volume":"9","author":"Grayson","year":"2017","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.neuropharm.2020.108442_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1634","article-title":"A Phase 2, Double-blind, placebo-controlled trial to investigate potential drug-drug interactions between cannabidiol and clobazam","author":"VanLandingham","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels","volume":"75","author":"Vilela","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib88","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12974-019-1618-x","article-title":"TRPV1 translocated to astrocytic membrane to promote migration and inflammatory infiltration thus promotes epilepsy after hypoxic ischemia in immature brain","volume":"16","author":"Wang","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib89","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40262-020-00869-z","article-title":"Disposition of oral cannabidiol-rich cannabis extracts in children with epilepsy","volume":"59","author":"Wang","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2020.108442_bib90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.brainresbull.2018.11.008","article-title":"The role of adenosine in epilepsy","volume":"151","author":"Weltha","year":"2019","journal-title":"Brain Res. Bull."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib91","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40263-019-00624-4","article-title":"INS011-14-029 Study Investigators. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy","volume":"33","author":"Wheless","year":"2019","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108442_bib92","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol interacts significantly with everolimus-Report of a aatient with tuberous sclerosis complex","volume":"50","author":"Wiemer-Kruel","year":"2019","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108442_bib93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1152\/jn.01023.2006","article-title":"TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons","volume":"97","author":"Xing","year":"2007","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2020.108442_bib94","doi-asserted-by":"crossref","first-page":"105128","DOI":"10.1016\/j.phrs.2020.105128","article-title":"Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1\/GluA2","author":"Yu","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108442_bib95","first-page":"3448","article-title":"Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines","volume":"8","author":"Zgair","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108442_bib96","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108442_bib97","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11940-018-0537-y","article-title":"Current treatment strategies and future treatment options for Dravet syndrome","volume":"20","author":"Ziobro","year":"2018","journal-title":"Curr. Treat. Options Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820305104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820305104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:07:19Z","timestamp":1758438439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820305104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":98,"alternative-id":["S0028390820305104"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108442","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108442"}}